Companies Dominating the Autoimmune Disease Treatment Market
Currently, a significant revenue share of 48.2% in the autoimmune treatment market is controlled by the collective output from AbbVie, J&J, Roche, Novartis, and Pfizer. Their strategic augmentation toward product innovation and commercialization helped consolidate this leadership. In addition, they are proactively investing and involved in the cohort of extensive exploration and penetration of their existing pipelines while maintaining alignment with the latest autoimmune disease treatment market trends. For instance, in 2025, Novartis advanced its CAR-T therapy portfolio to expand applications for treating lupus. Similarly, BMS allocated USD 14.3 billion in capital to leverage its leadership in immunology by acquiring Turning Point.
Top 20 of this cohort of innovators inclue:
|
Company Name |
Country |
Market Share |
Industry Focus |
|
AbbVie |
U.S. |
12.6% |
Leader in biologics (Humira, Skyrizi for psoriasis/RA) |
|
Johnson & Johnson |
U.S. |
10.3% |
Immunology blockbusters (Stelara, Tremfya) |
|
Roche |
Switzerland |
9.9% |
Biologics (Rituxan, Actemra) + companion diagnostics |
|
Novartis |
Switzerland |
8.7% |
CAR-T therapies (Kymriah for lupus) & Cosentyx (psoriasis/AS) |
|
Pfizer |
U.S. |
7.5% |
JAK inhibitors (Xeljanz for RA) & biosimilars |
|
Amgen |
U.S. |
xx% |
Enbrel (RA), biosimilars (Amjevita) |
|
Bristol-Myers Squibb |
U.S. |
xx% |
Orencia (RA), Sotyktu (psoriasis) |
|
Eli Lilly |
U.S. |
xx% |
Taltz (psoriasis/AS), Olumiant (RA) |
|
UCB |
Belgium |
xx% |
Cimzia (RA/psoriasis), neurology-autoimmune pipeline |
|
Sanofi |
France |
xx% |
Dupixent (eczema/asthma), autoimmune rare disease focus |
|
Merck KGaA |
Germany |
xx% |
Rebif (multiple sclerosis), Erbitux (RA) |
|
Takeda |
Japan |
xx% |
Entyvio (IBD), plasma-derived therapies |
|
AstraZeneca |
UK |
xx% |
Fasenra (eosinophilic diseases), rare autoimmune pipeline |
|
Gilead Sciences |
U.S. |
xx% |
Jyseleca (RA), Kite Pharma CAR-T expansion |
|
Biogen |
U.S. |
xx% |
MS drugs (Tysabri, Tecfidera) |
|
Celltrion |
South Korea |
xx% |
Biosimilars (Remsima, Truxima) dominating EU/Asia |
|
Daiichi Sankyo |
Japan |
xx% |
Collaborations with U.S./EU firms on RA/psoriasis |
|
Biocon |
India |
xx% |
Biosimilars (adalimumab, trastuzumab) for cost-sensitive markets |
|
CSL Limited |
Australia |
xx% |
Plasma therapies for autoimmune disorders (Privigen) |
|
Pharmaniaga |
Malaysia |
xx% |
Localized biosimilars & insulin for ASEAN markets |
